Brief: Unity Biotech Doses First Patient In Envision, Phase 2 Study Of UBX1325
19/04/2022 13:12
April 19 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY DOSES FIRST PATIENT IN ENVISION, THE
PHASE 2
STUDY OF UBX1325 IN WET AGE-RELATED MACULAR DEGENERATION
Source text for Eikon: ID:nGNX24Q5gv
Further company coverage: UBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force